LIMNLiminatus Pharma, Inc.vs its industry peers
A metric-by-metric comparison of Liminatus Pharma, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIMNEsta | $169M#8 | — | 563.0x#13 | — | — | -187.8%#13 | — | -3395.2%#13 | -170.3%#3 | — | -96.2%#14 | — |
| PALI | $216M#1 | 1.9x#1 | 1.8x#7 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | -37.8%#7 | — |
| PLX | $209M#2 | 11.3x#2 | 2.9x#9 | 4.0x#5 | -1.2%#4 | -325.2%#14 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 9.3%#3 | — |
| IKT | $208M#3 | — | 1.4x#6 | — | -100.0%#7 | -75.4%#11 | — | -31.5%#6 | — | — | -8.0%#5 | — |
| ARTV | $206M#4 | — | 0.6x#1 | — | -100.0%#7 | -28.3%#7 | — | -24.1%#4 | — | — | 12.0%#2 | — |
| DTIL | $194M#5 | 21.7x#3 | 3.7x#11 | 5.7x#6 | -50.1%#6 | -738.0%#15 | -152.2%#3 | -88.3%#11 | — | — | -6.1%#4 | — |
| ACOG | $180M#6 | — | 3.4x#10 | 17.6x#7 | — | -39.8%#10 | -221.7%#5 | -39.0%#8 | — | — | 44.0%#1 | — |
| IVVD | $172M#7 | — | 1.0x#5 | 3.2x#4 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#5 | — | — | -63.5%#10 | — |
| STRO | $157M#9 | — | — | 1.5x#1 | 65.2%#2 | 15.9%#5 | -154.5%#4 | — | — | — | -12.9%#6 | — |
| TARA | $144M#10 | — | 0.9x#4 | 48.7x#8 | — | -28.7%#8 | -2189.6%#8 | -35.6%#7 | — | — | — | — |
| CMPX | $138M#11 | — | 0.8x#3 | — | -100.0%#7 | -34.7%#9 | — | -40.0%#9 | — | — | -79.5%#13 | — |
| CHRS | $124M#12 | — | 2.0x#8 | 3.0x#3 | 59.8%#3 | 489.4%#1 | -429.5%#7 | 276.2%#1 | -351.2%#4 | — | -49.3%#8 | — |
| HUMA | $122M#13 | — | 3.9x#12 | 59.7x#9 | — | 72.5%#2 | -5306.0%#10 | -130.6%#12 | — | — | -72.4%#12 | — |
| ARMP | $114M#14 | — | — | — | — | -818.8%#16 | — | — | — | — | — | 0.1%#1 |
| VYGR | $113M#15 | — | 0.7x#2 | 2.8x#2 | -49.5%#5 | -84.2%#12 | -326.6%#6 | -77.6%#10 | — | — | -59.9%#9 | — |
| OTLK | $112M#16 | — | — | 79.3x#10 | — | 17.2%#4 | -4744.3%#9 | — | -12.8%#2 | — | -64.7%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice